palbociclib.
drug for the treatment of ER-positive and HER2-negative breast cancer developed by Pfizer
AstraZeneca Breast Cancer Trial Misses Key Goal
AstraZeneca’s breast cancer pill camizestrant (Etcamah) failed to improve progression-free survival in a late-stage trial when added to standard therapy, despite an earlier ESR1 mutation–targeted approval and after-hours stock weakness. The broader trial that reached more patients failed, while a separate study in ESR1-mutant patients showed a meaningful benefit, underscoring a split outcome for the drug’s potential.
Health · 10 sources · Sep 12, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About palbociclib
Palbociclib, sold under the brand name Ibrance among others, is an anti-cancer medication used for the treatment of HR-positive and HER2-negative breast cancer. It was developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.
Everything about palbociclib →